Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
18 hedge funds and large institutions have $1.41M invested in Immune Pharmaceuticals Inc. in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
48% more capital invested
Capital invested by funds: $949K → $1.41M (+$458K)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
6% more funds holding
Funds holding: 17 → 18 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$181K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$172K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$113K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$32K |
| 5 |
Goldman Sachs
New York
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$60K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$52.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$19K |
| 5 |
Bank of New York Mellon
New York
|
-$14K |
IMNP Hedge Fund Activity: Q2 2017 in Review
18 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q2 2017, worth a combined $1.41M — up 48% from $949K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IMNP positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $181K. The largest seller was Geode Capital Management, cutting an estimated $60K.
- 18 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q2 2017, up from 17 in Q1 2017.
- Funds reported $1.41M of Immune Pharmaceuticals Inc. stock for Q2 2017, up 48% quarter-over-quarter.
- 6 funds opened new Immune Pharmaceuticals Inc. positions in Q2 2017 and 5 closed out, a net change of +1 holder.
- The largest Immune Pharmaceuticals Inc. buyer in Q2 2017 was Susquehanna International Group, an estimated $181K added.
- The largest Immune Pharmaceuticals Inc. seller in Q2 2017 was Geode Capital Management, an estimated $60K sold.
Based on aggregated 13F filings for Q2 2017.